Larvol Veri

CANCER:

Lung Cancer

PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval Roche Press Release - 2 days atezolizumab Sensitive : A1 Roche Press Release - 2d
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Biocon Press Release - 1 week Krabeva (bevacizumab biosimilar) Sensitive : A1 Biocon Press Release - 1wk
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A2 - Guideline Asia Pac J Clin Oncol - 1 week osimertinib Sensitive : A2 Asia Pac J Clin Oncol - 1wk
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval AstraZeneca Press Release - 1 week osimertinib Sensitive : A1 AstraZeneca Press Release - 1wk
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval AstraZeneca Press Release - 1 week osimertinib Sensitive : A1 AstraZeneca Press Release - 1wk
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval Expert Rev Anticancer Ther - 1 week brigatinib Sensitive : A1 Expert Rev Anticancer Ther - 1wk
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval ESMO Open - 1 week entrectinib Sensitive : A1 ESMO Open - 1wk
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	TAK-788 Sensitive: B - Late Trials Takeda Press Release - 1 week TAK-788 Sensitive : B Takeda Press Release - 1wk
CALR elevation CALR elevation	Non Small Cell Lung Cancer NSCLC	docetaxel Sensitive: C3 – Early Trials Lung Cancer - 1 week docetaxel Sensitive : C3 Lung Cancer - 1wk
CALR elevation CALR elevation	Non Small Cell Lung Cancer NSCLC	pemetrexed Sensitive: C3 – Early Trials Lung Cancer - 1 week pemetrexed Sensitive : C3 Lung Cancer - 1wk
CALR elevation + EGFR mutation CALR elevation + EGFR mutation	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C3 – Early Trials Lung Cancer - 1 week osimertinib Sensitive : C3 Lung Cancer - 1wk
EGFR T790M + C797S EGFR T790M + C797S	Lung Adenocarcinoma LUAD	gefitinib + osimertinib Resistant: C4 – Case Studies Onco Targets Ther - 1 week gefitinib + osimertinib Resistant : C4 Onco Targets Ther - 1wk
EGFR T790M + C797S EGFR T790M + C797S	Lung Adenocarcinoma LUAD	osimertinib + anlotinib Sensitive: C4 – Case Studies Onco Targets Ther - 1 week osimertinib + anlotinib Sensitive : C4 Onco Targets Ther - 1wk
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 2 weeks nivolumab + ipilimumab Sensitive : A1 Bristol-Myers Squibb Press Release - 2wk
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A2 - Guideline J Clin Oncol - 2 weeks pembrolizumab Sensitive : A2 J Clin Oncol - 2wk
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A2 - Guideline Cancer Treat Res Commun - 2 weeks erlotinib + ramucirumab Sensitive : A2 Cancer Treat Res Commun - 2wk
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: C3 – Early Trials Future Oncol - 2 weeks EGFR inhibitor Sensitive : C3 Future Oncol - 2wk
NCOR2-NTRK1 fusion + TMB-H NCOR2-NTRK1 fusion + TMB-H	Lung Adenocarcinoma LUAD	camrelizumab Resistant: C4 – Case Studies BMC Pulm Med - 2 weeks camrelizumab Resistant : C4 BMC Pulm Med - 2wk
NCOR2-NTRK1 fusion + TMB-H NCOR2-NTRK1 fusion + TMB-H	Lung Adenocarcinoma LUAD	larotrectinib Sensitive: C4 – Case Studies BMC Pulm Med - 2 weeks larotrectinib Sensitive : C4 BMC Pulm Med - 2wk
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval ESMO.org - 3 weeks durvalumab Sensitive : A1 ESMO.org - 3wk
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval ESMO.org - 3 weeks atezolizumab Sensitive : A1 ESMO.org - 3wk
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	topotecan Sensitive: A1 - Approval ESMO.org - 3 weeks topotecan Sensitive : A1 ESMO.org - 3wk
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	lurbinectedin Sensitive: A1 - Approval ESMO.org - 3 weeks lurbinectedin Sensitive : A1 ESMO.org - 3wk
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks nivolumab Sensitive : A1 Bristol-Myers Squibb Press Release - 3wk
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	CAV Sensitive: A2 - Guideline ESMO.org - 3 weeks CAV Sensitive : A2 ESMO.org - 3wk
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: A2 - Guideline Front Oncol - 3 weeks EGFR inhibitor Sensitive : A2 Front Oncol - 3wk
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	cisplatin Sensitive: A2 - Guideline ESMO.org - 3 weeks cisplatin Sensitive : A2 ESMO.org - 3wk
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	carboplatin Sensitive: A2 - Guideline ESMO.org - 3 weeks carboplatin Sensitive : A2 ESMO.org - 3wk
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	carboplatin + etoposide IV Sensitive: A2 - Guideline ESMO.org - 3 weeks carboplatin + etoposide IV Sensitive : A2 ESMO.org - 3wk
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	cisplatin + etoposide IV Sensitive: A2 - Guideline ESMO.org - 3 weeks cisplatin + etoposide IV Sensitive : A2 ESMO.org - 3wk
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	carboplatin + gemcitabine Sensitive: A2 - Guideline ESMO.org - 3 weeks carboplatin + gemcitabine Sensitive : A2 ESMO.org - 3wk
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	cisplatin + topotecan Sensitive: A2 - Guideline ESMO.org - 3 weeks cisplatin + topotecan Sensitive : A2 ESMO.org - 3wk
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	cisplatin + irinotecan Sensitive: A2 - Guideline ESMO.org - 3 weeks cisplatin + irinotecan Sensitive : A2 ESMO.org - 3wk
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval JTO Clin Res Rep - 3 weeks erlotinib + ramucirumab Sensitive : A1 JTO Clin Res Rep - 3wk
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval JTO Clin Res Rep - 3 weeks erlotinib + ramucirumab Sensitive : A1 JTO Clin Res Rep - 3wk
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: A2 - Guideline J Formos Med Assoc - 3 weeks bevacizumab Sensitive : A2 J Formos Med Assoc - 3wk
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline Tumori - 3 weeks crizotinib Sensitive : A2 Tumori - 3wk
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: C2 – Inclusion Criteria J Formos Med Assoc - 3 weeks bevacizumab Sensitive : C2 J Formos Med Assoc - 3wk
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	D-0316 Sensitive: C2 – Inclusion Criteria AACR 2021 - 3 weeks D-0316 Sensitive : C2 AACR 2021 - 3wk
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: C3 – Early Trials Lung Cancer - 3 weeks Immunotherapy Sensitive : C3 Lung Cancer - 3wk
BRAF mutation BRAF mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials Eur J Cancer - 3 weeks PD-L1 inhibitor Sensitive : C3 Eur J Cancer - 3wk
BRAF mutation BRAF mutation	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Sensitive: C3 – Early Trials Eur J Cancer - 3 weeks PD1 inhibitor Sensitive : C3 Eur J Cancer - 3wk
MET amplification MET amplification	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C3 – Early Trials Tumori - 3 weeks crizotinib Sensitive : C3 Tumori - 3wk
XAGE1 antibody elevation XAGE1 antibody elevation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Clin Chim Acta - 3 weeks Immunotherapy Sensitive : C3 Clin Chim Acta - 3wk
CTAG1B antibody elevation + XAGE1 antibody elevation CTAG1B antibody elevation + XAGE1 antibody elevation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Clin Chim Acta - 3 weeks Immunotherapy Sensitive : C3 Clin Chim Acta - 3wk
CTAG1B antibody elevation CTAG1B antibody elevation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Clin Chim Acta - 3 weeks Immunotherapy Sensitive : C3 Clin Chim Acta - 3wk
MGAM mutation MGAM mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: C3 – Early Trials Front Pharmacol - 3 weeks Immunotherapy Sensitive : C3 Front Pharmacol - 3wk
PTGR1 expression PTGR1 expression	Non Small Cell Lung Cancer NSCLC	LP-184 Sensitive: D – Preclinical Oncotarget - 3 weeks LP-184 Sensitive : D Oncotarget - 3wk
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	capmatinib Sensitive: A1 - Approval capmatinib Sensitive : A1
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : A1
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	DP Sensitive: A1 - Approval DP Sensitive : A1
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES